These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35731793)

  • 1. Comparison of external R&D and internal R&D: Based on the perspective of S&T development of China's pharmaceutical manufacturing industry.
    Wu D; Wang S; Chang S; Lian G; Chen Y
    PLoS One; 2022; 17(6):e0270271. PubMed ID: 35731793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Technological Innovation Affect China's Pharmaceutical Smart Manufacturing Industrial Upgrading.
    Wang S; Chen Y
    J Healthc Eng; 2021; 2021():3342153. PubMed ID: 34868514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent research and development, technology accumulation and innovation performance: Evidence from China's pharmaceutical manufacturing industry.
    Wang S; Liu Q; Chen Y
    PLoS One; 2022; 17(4):e0266768. PubMed ID: 35390101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diminishing marginal contribution of R&D investment on green technological progress: a case study of China's manufacturing industry.
    Zhang X; Li R; Zhang J
    Environ Sci Pollut Res Int; 2023 Feb; 30(6):14190-14199. PubMed ID: 36151434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Threshold effects of energy consumption, technological innovation, and supply chain management on enterprise performance in China's manufacturing industry.
    Liu H; Fan L; Shao Z
    J Environ Manage; 2021 Dec; 300():113687. PubMed ID: 34530370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measure on innovation efficiency of China's pharmaceutical manufacturing industry.
    Zhong S; Liang S; Zhong Y; Zheng Y; Wang F
    Front Public Health; 2022; 10():1024997. PubMed ID: 36504962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional technology gap and innovation efficiency trap in Chinese pharmaceutical manufacturing industry.
    Lai H; Shi H; Zhou Y
    PLoS One; 2020; 15(5):e0233093. PubMed ID: 32433705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Has the consistency evaluation policy of generic drugs promoted the innovation quality of Chinese pharmaceutical manufacturing industry? An empirical study based on the difference-in-differences model.
    Liu Q; Huang Z; Mao Z
    Front Public Health; 2023; 11():1265756. PubMed ID: 38106910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research on the impact of technology mergers and acquisitions on corporate performance: an empirical analysis based on China's pharmaceutical industry.
    Yang J; Li J; Wang S; Chen Y
    Front Public Health; 2024; 12():1419305. PubMed ID: 39185128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of the Drug Marketing Authorization Holder system on sustainable improvement of innovation quality in the pharmaceutical manufacturing industry in China-An empirical study using synthetic control methods.
    Liu Q; Wang S; Huang Z
    PLoS One; 2024; 19(7):e0304056. PubMed ID: 38968168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research on the impact of China's reform to delegate power, streamline administration, and optimize government services on the technology innovation efficiency of the pharmaceutical manufacturing industry.
    Gu Y; Zhuang Q
    Front Public Health; 2024; 12():1325298. PubMed ID: 38344238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does China's national volume-based drug procurement policy promote or hinder pharmaceutical innovation?
    Li X; Xu J
    Front Pharmacol; 2024; 15():1392239. PubMed ID: 38994196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the development efficiency of the green economy in China's equipment manufacturing industry.
    Li W; Ouyang X
    Environ Sci Pollut Res Int; 2020 Jul; 27(19):24070-24080. PubMed ID: 32304048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R&D Investments, Debt Capital, and Ownership Concentration: A Three-Way Interaction and Lag Effects on Firm Performance in China's Pharmaceutical Industry.
    Su CY; Guo YN; Chai KC; Kong WW
    Front Public Health; 2021; 9():708832. PubMed ID: 34660511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Environmental Performance on Employment: Evidence from China's Manufacturing Industries.
    Shan W; Wang J
    Int J Environ Res Public Health; 2019 Jun; 16(12):. PubMed ID: 31242548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Public funding and private investment for R&D: a survey in China's pharmaceutical industry.
    Qiu L; Chen ZY; Lu DY; Hu H; Wang YT
    Health Res Policy Syst; 2014 Jun; 12():27. PubMed ID: 24925505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Government R&D Subsidies, Environmental Regulations, and Their Effect on Green Innovation Efficiency of Manufacturing Industry: Evidence from the Yangtze River Economic Belt of China.
    Yi M; Wang Y; Yan M; Fu L; Zhang Y
    Int J Environ Res Public Health; 2020 Feb; 17(4):. PubMed ID: 32092916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American export control, technology spillover and innovation of Chinese pharmaceutical Industry.
    Hui J
    Pak J Pharm Sci; 2017 May; 30(3(Special)):1151-1155. PubMed ID: 28671099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The synergy degree measurement and transformation path of China's traditional manufacturing industry enabled by digital economy.
    Liu Y; Zhao X; Mao F
    Math Biosci Eng; 2022 Apr; 19(6):5738-5753. PubMed ID: 35603376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbon emission reduction characteristics for China's manufacturing firms: Implications for formulating carbon policies.
    An Y; Zhou D; Yu J; Shi X; Wang Q
    J Environ Manage; 2021 Apr; 284():112055. PubMed ID: 33540202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.